Clinical trial · Observational
PAncreatic Disease Cohort of TOuLouse
NCT05824403CI-TRIAL-00071924PACTOLrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a prospective cohort dedicated to pancreatic diseases excluding cancer. The aim is to develop positive or differential diagnostic tools between benign potentially malignant or malignant pancreatic pathologies. During this study the investigators collect data and biological samples to support research project.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Diseases | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Diagnostic tools
- timeFrame
- 3 years after the first inclusion
- description
- To develop positive or differential diagnostic tools between benign potentially malignant or malignant pancreatic pathologies
Secondary outcomes (4)
- measure
- New targets
- timeFrame
- 3 years after the first inclusion
- description
- To identify new screening targets
- measure
- Improvement of management
- timeFrame
- 3 years after the first inclusion
- description
- To improve the management of cystic lesions or Chronic pancreatitis on the decision of therapeutic management
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with inflammatory or cystic exocrine pancreatic pathology * Patient able to read and understand the information leaflet * Patients who have agreed to participate in the study and have signed the free and informed consent * Patients affiliated to a social security system (including AME) Exclusion Criteria: * Patient with pancreatic cancer pathology * Patients with active cancer, whatever the origin * Pregnant or breastfeeding patients * Patients under legal protection, guardianship or trusteeship
References
Publications (1)
- DERIVEDBardol T, Dujon AM, Taly V, Dunyach-Remy C, Lavigne JP, Costa-Silva B, Kurma K, Eslami-S Z, Cayrefourcq L, Canivet C, Muscari F, Bournet B, Alix-Panabieres C. Early detection of pancreatic cancer by liquid biopsy "PANLIPSY": a french nation-wide study project. BMC Cancer. 2024 Jun 10;24(1):709. doi: 10.1186/s12885-024-12463-8. PMID 38853244